Prostate cancer metastasis to the distal phalanx of the left hallux: The first confirmed case and literature review

XINBING SUI1*, YAN HU2*, CHENG ZHANG3, HONGMING PAN1 and DA LI1

Departments of 1Medical Oncology and 2Pathology, Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou, Zhejiang 310016; 3Department of Medical Oncology, The Affiliated Hospital of Hangzhou Normal University, Hangzhou, Zhejiang 310015, P.R. China

Received April 14, 2015; Accepted May 26, 2016

DOI: 10.3892/ol.2016.4701

Abstract. Prostate cancer is one of the most common carcinomas in Asia, as well as all over the world. The vast majority of prostate cancer patients present with bone metastases, which mainly involve the axial bones, with pain as the most common symptom. The present study reports the first case of prostate cancer metastasis to the hallux in a 73-year-old man who presented with pain and a swollen phalanx of the left hallux. This symptom developed gradually over a period of several months and could not be improved with the common treatments. Due to a pathological fracture, amputation of the left phalanx was performed. Notably, the immunohistochemical examinations of the surgical sample demonstrated the presence of a metastatic lesion from prostate cancer. The present study describes an unusual presentation involving phalangeal metastasis in a prostate cancer patient, and a systematic review of reported cases of rare metastatic events in prostate cancer is also discussed.

Introduction

Prostate cancer is the most common carcinoma in males around the world and the fifth most common cause of cancer-associated mortality. The majority of prostate cancer patients succumb to metastatic disease (1). Distant metastases are the most common cause of cancer-associated mortality in prostate cancer patients (2). The bone is a common site of metastasis in prostate cancer and this type of metastasis presents in >80% of patients who succumb to prostate cancer (3). The bone metastatic lesions from prostate cancer show more osteoblastic than osteolytic bone lesions compared with those that originate from other cancer types (4). Metastases to the bone mainly involve the axial bones, and prostate cancer rarely metastasizes to the distal phalanges. The current study reports the case of a patient with prostate cancer that metastasized to the distal phalanx of the left hallux. A systematic review of the associated literature regarding prostate cancer with non-axial bone metastasis is also presented. Written informed consent was obtained from the patient.

Case report

On July 4, 2014, a 73-year-old man was admitted to the Sir Run Run Shaw Hospital (Hangzhou, Zhejiang, China) due to pain and swelling of the distal phalanx of the left hallux, which had developed gradually over several months and progressed during the last 2 weeks prior to the patient’s initial visit. The patient did not complain of any fever or changes in toe movement. The patient’s medical history did not include any recent injuries. On November 28, 2012, the patient had been diagnosed with prostate cancer by prostate biopsy in Zhejiang Province People’s Hospital (Hangzhou, Zhejiang, China), and in November 2013 the patient had been diagnosed with lung and vertebral bone metastases, as determined by positron emission tomography/computed tomography (PET/CT) and bone scans in the same hospital.

Due to the prostate cancer, the patient was treated with radioactive particle implantation in the prostate (iodine 125; 150 Gy), endocrine therapy with casodex (50 mg 3 times a day; December 2, 2012-April 9, 2013) and goserelin acetate (3.6 mg subcutaneous once every 28 days; December 2, 2012-April 9, 2013), chemotherapy with docetaxel in combination with prednisone (100 mg intravenous every 3 weeks; May 9, 2013-December 3, 2013), and endocrine therapy with abiraterone (1000 mg daily; January 14, 2014-July 4, 2014).

 Upon the current admission, the physical examination did not reveal any abnormalities. The white blood cell, hemoglobin and platelet counts were 6,750 cells/mm³ (normal range, 3,500-9,500 cells/mm³), 11.4 g/dl (13.0-17.5 g/dl) and 110,000 cells/mm³ (normal range, 100,000-300,000 cells/mm³), respectively. The patient had a high serum prostate-specific antigen (PSA) level (>10,000 ng/ml; normal range, <4 ng/ml). An enhanced CT scan of the chest and abdomen showed a large...
As the patient was admitted due to a swollen distal phalanx of the left hallux, a bone scan or PET/CT scan was indicated, however, the patient refused. Therefore, an X-ray examination was performed (Fig. 1B). The X-ray results showed morphological changes of the phalanx and surrounding soft-tissue swelling. Moreover, an obvious swelling was found on the terminal phalanx of the toe. The patient was first treated with incision and drainage of the soft tissue, but the swelling symptom could not be improved. On the contrary, it became more and more serious during the next 2 weeks, accompanied with osteolytic destruction (Fig. 1B). After an orthopedic consultation, an amputation of the phalanx of the left hallux was performed (Fig. 1C).

The patient was discharged a week after surgery. A follow-up visit every week was scheduled and no post-operative complications occurred. The resected specimen (4 µm) was analyzed by histological (hematoxylin and eosin) and immunohistochemical

Table I. Characteristics of patients with prostate cancer presenting with rare metastatic events.

<table>
<thead>
<tr>
<th>First author</th>
<th>Year</th>
<th>Age, years</th>
<th>Site</th>
<th>PSA, ng/ml</th>
<th>(Ref.)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Massraf and Wand</td>
<td>1998</td>
<td>62</td>
<td>Thumb</td>
<td>396,000</td>
<td>(7)</td>
</tr>
<tr>
<td>Patel et al</td>
<td>2015</td>
<td>93</td>
<td>Cutaneous; proximal right lower trunk</td>
<td>415</td>
<td>(8)</td>
</tr>
<tr>
<td>Ogunmola et al</td>
<td>2013</td>
<td>62</td>
<td>Cutaneous; neck, limbs and trunk</td>
<td>Unknown</td>
<td>(9)</td>
</tr>
<tr>
<td>Brown et al</td>
<td>2014</td>
<td>73</td>
<td>Cutaneous; left chest</td>
<td>47</td>
<td>(10)</td>
</tr>
<tr>
<td>Keen and Hassan</td>
<td>2013</td>
<td>70</td>
<td>Cutaneous; left inguinal region and inner left thigh</td>
<td>210</td>
<td>(11)</td>
</tr>
<tr>
<td>Martin et al</td>
<td>2015</td>
<td>66</td>
<td>Iris</td>
<td>17</td>
<td>(12)</td>
</tr>
<tr>
<td>Soe et al</td>
<td>2014</td>
<td>64</td>
<td>Stomach and rectum</td>
<td>&gt;10,000</td>
<td>(13)</td>
</tr>
<tr>
<td>Hélissey et al</td>
<td>2015</td>
<td>87</td>
<td>Parotid gland</td>
<td>227</td>
<td>(14)</td>
</tr>
<tr>
<td>Zhang et al</td>
<td>2014</td>
<td>76</td>
<td>Proximal ureter</td>
<td>18.14</td>
<td>(15)</td>
</tr>
<tr>
<td>Kaswala et al</td>
<td>2014</td>
<td>42</td>
<td>Duodenum</td>
<td>Unknown</td>
<td>(16)</td>
</tr>
<tr>
<td>Wu et al</td>
<td>2014</td>
<td>74</td>
<td>Intramedullary spinal cord</td>
<td>Unknown</td>
<td>(17)</td>
</tr>
<tr>
<td>Oliveira et al</td>
<td>2012</td>
<td>73</td>
<td>Larynx</td>
<td>78</td>
<td>(18)</td>
</tr>
<tr>
<td>Freudlsperger et al</td>
<td>2012</td>
<td>75</td>
<td>Mandibular condyle</td>
<td>Unknown</td>
<td>(19)</td>
</tr>
</tbody>
</table>

PSA, prostate-specific antigen.
staining. Notably, histological examination revealed a large island of tumor cells (Fig. 2). Immunohistochemical analysis revealed that the tumor cells were positive for protein kinase P504S, PSA and cytokeratin (CK)7 (Fig. 2), whereas the cells were negative for cluster of differentiation (CD)56, synaptophysin (Syn), chromogranin A (CgA) and neuron-specific enolase (NSE). The following antibodies were used: Mouse monoclonal anti-P504S (catalog number, sc-81710; dilution, 1:500; Santa Cruz Biotechnology, Inc., Dallas, TX, USA), mouse monoclonal anti-PSA (catalog number, sc-7316; dilution, 1:500; Santa Cruz Biotechnology, Inc.), mouse monoclonal anti-CK7 (catalog number, ab-9021; dilution, Abcam, Cambridge, MA, USA), mouse monoclonal anti-CD56 (catalog number, 3576; dilution, 1:100; Cell Signaling Technology, Inc., Danvers, MA, USA), mouse monoclonal anti-Syn (catalog number, sc-398849; dilution, 1:500; Santa Cruz Biotechnology, Inc.), rabbit polyclonal anti-CgA (catalog number, ab-15160; dilution, 1:1,000; Abcam) and rabbit polyclonal anti-NSE (catalog number, ab-53025; dilution, 1:1,000; Abcam). Taken together, these analyses confirmed that the lesion of the distal phalanx of the left hallux was a metastatic mass from prostate cancer.

Based on the aforementioned evidence, a diagnosis of prostate cancer with metastasis to the distal phalanx of the left hallux was made. The patient succumbed to cardiac and respiratory failure on February 15, 2015.

Discussion

Prostate cancer is the most common noncutaneous cancer in men around the world and it preferentially spreads to the skeleton. Therefore, bone is the dominant and often only metastatic lesion for the vast majority of men with advanced prostate cancer (5). Bone metastasis is the main cause for the morbidity and mortality associated with prostate cancer, leading to skeletal-related events that include severe pain, pathological fractures and the risk of spinal cord compromise (6). The non-axial bone metastasis of prostate cancer is an extremely rare event. Only phalangeal thumb metastasis has been reported to date (7). Besides bone, lymph node, lung, liver, pleura and adrenal gland metastases, several rare metastatic events have been reported in prostate cancer patients. Although cutaneous metastasis from prostate cancer is rare in the literature, it has recently been

Figure 2. Pathological features with histological and immunohistochemical staining for P504S, PSA and CK7. Histological examination revealed a large island of tumor cells. Immunohistochemical staining revealed that the specimen cells were positive for P504S, PSA and CK7. PSA, prostate-specific antigen; CK7, cytokeratin 7; H&E, hematoxylin and eosin.
reported in a large number of the case studies (Table I) (8-11). In addition, the iris (12), gastrointestinal tract (13), parotid gland (14), proximal ureter (15), duodenum (16), intramedullary spinal cord (17), larynx (18) and mandibular condyle (19) are also involved metastatic sites of prostate cancer. Nonetheless, prostate cancer with metastasis to the phalanx of the toe has not been reported to date. The present case is therefore the first report on this rare type of metastasis.

Several tumor markers are useful in determining the diagnosis of prostate cancer. PSA is a specific tumor marker for prostate cancer that commonly occurs at high serum levels in affected patients (20). PSA evaluation by immunohistochesmistry has been demonstrated to be a useful tool for determining the diagnosis and prognosis of prostate cancer (21). However, PSA immunohistochemistry for the detection of metastatic prostate cancer can also be of limited utility (22). In the present case, the immunoreactivity of PSA staining tended to be mildly positive in the metastatic site.

α-methylacyl-CoA racemase (AMACR/P504S) is a metabolic enzyme whose overexpression has been shown to be a diagnostic indicator of prostatic adenocarcinoma in clinical practice (23,24). Increasing evidence has shown AMACR/P504S is a diagnostically useful marker for prostatic cancer (25,26). In the present study, immunohistochemical examinations revealed positive P504S staining in the surgical sample. CK7 is commonly used to identify primary tumor sites and to distinguish invasive prostate cancer from cancer in situ (27). However, the immunohistochemical examination of CK7 is not specific for prostatic cancer. Focal positivity for CK7 was found in the present results.

The neuroendocrine antigens (NSE, CgA, Syn and CD56) are useful in identifying neuroendocrine prostate cancer, but are usually not expressed in prostatic adenocarcinoma (28). In agreement with this, the present immunohistochemical staining also showed negative results for CD56, Syn, CgA and NSE in prostatic adenocarcinoma.

In summary, the present study is the first to report a case of prostate cancer metastasis to the phalanx of the toe, in a man that was referred because of persistent pain and swelling of the distal phalanx of the left hallux, initially misdiagnosed and treated as abscess. No post-surgery complications and recurrence occurred following local surgery. The observations made in the present study contribute to a better understanding of bone metastasis of prostate cancer.

Acknowledgements

This study was supported by grants from the National Natural Science Foundation of China (no. 81301891), the Zhejiang Provincial Natural Science Foundation of China (no. LQ13H160008), the Zhejiang Province Science and Technology Project of Traditional Chinese Medicine (no. 2015ZB033) and the Zhengshu Medical Elite Scholarship Fund.

References


